摘要
目的 探讨全脑放疗联合局部加量放疗在非小细胞肺癌(non-small cell lung cancer, NSCLC)脑寡转移患者中的临床疗效。方法 选取2020年3月至2023年5月期间收治的73例NSCLC脑寡转移患者,将其分为对照组(37例,接受全脑放疗)和研究组(36例,接受全脑放疗联合局部加量放疗)。通过头部增强MRI检查在放疗前后进行评估,依据实体瘤客观疗效标准(RECIST 1.1版)比较两组的近期疗效、生存时间、脑损伤情况及不良反应发生率。结果 研究组的临床有效率为75.00%(27/36),高于对照组的64.86%(24/37),但差异无统计学意义(P>0.05)。研究组中位生存期为8.25个月,而对照组为6.82个月。研究组3个月和6个月的生存率分别为86.11%和69.44%,对照组分别为91.89%和59.46%,差异无统计学意义(P>0.05)。然而,研究组12个月生存率为50%,显著高于对照组的21.62%,差异有统计学意义(P<0.05)。两组患者在放疗期间主要出现1~2级的头痛、头晕、恶心、呕吐、骨髓抑制和食欲下降等不良反应,两组间不良反应发生率无显著差异(P>0.05)。结论对于NSCLC脑寡转移患者,全脑放疗联合局部加量放疗可在一定程度上提高临床有效率,并显著改善12个月生存率,同时不增加放疗期间的不良反应,安全性良好。
Objective To investigate the clinical efficacy of whole brain radiotherapy(WBRT)combined with local dose-boost radiotherapy in patients with oligometastatic non-small cell lung cancer(NSCLC).Methods A total of 73 patients with NSCLC brain oligometastases treated between March 2020 and May 2023were divided into a control group(37 cases,receiving WBRT)and a study group(36 cases,receiving WBRT combined with local dose-boost radiotherapy).Short-term efficacy was evaluated using head contrast-enhanced MRI before and after radiothera py according to RECIST 1.1 criteria.Su rvival tim e,brain injury,and the occurrence of adverse reactions were also compared between the two groups.Results The clinical effective rate was 75.00%(27/36)in the study group,higher than 64.86%(24/37)in the control group,though the difference was not statistically significa nt(P>0.05).The median su rvival time was 8.25 months in the study group compared to 6.82 months in the control group.The 3-month and 6-month survival rates were 86.11%and 69.44%in the study group,compared to 91.89%and59.46%in the control group,with no significa nt differences(P>0.05).However,the 12-month su rvival rate in the study group was significantly higher at 50%compared to 21.62%in the control group(P<0.05).The main adverse reactions during radiotherapy were grade 1-2 headache,dizziness,nausea,vomiting,bone marrow suppression,and appetite loss.There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion WBRT combined with local dose-boost radiotherapy may improve clinical efficacy and increase the 12-month su rvival rate in patients with NSCLC brain oligometastases without increasing adverse reactions during radiotherapy,indicating a favorable safety profile.
作者
王彦青
宋鹏慧
徐言东
边海波
WANG Yan-qing;SONG Peng-hui;XU Yan-dong;BIAN Hai-bo(Department of Radiotherapy,Changzhi People's Hospital,Changzhi 046000,Shanxi Province,China;Department of Radiotherapy,Heping Hospital Affiliated to Changzhi Medical College,Changzhi 046000,Shanxi Province,China)
出处
《中国CT和MRI杂志》
2025年第1期22-24,共3页
Chinese Journal of CT and MRI
基金
2021年度山西省基础研究计划(自由探索类)第二批项目资金(20210302124004)。
关键词
非小细胞肺癌
脑寡转移
全脑放疗
局部加量放疗
疗效
Non-small Cell Lung Cancer
Brain Oligometastasis
Whole Brain Radiotherapy
Local Dose Radiotherapy
Curative Effect
作者简介
第一作者/通讯作者:王彦青,男,副主任医师,主要研究方向:肿瘤的放射治疗。E-mail:yanqingwangfl@163.com。
